Image 1-Isturisa - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Isturisa (osilodrostat) for the Treatment of Cushing’s Disease

Image 1-Isturisa
Isturisa® (osilodrostat) is the first 11-beta‐hyrdoxylase enzyme inhibitor indicated to treat Cushing’s disease in adult patients, who are ineligible or failed pituitary surgery. Credit: US National Library of Medicine, National Institutes of Health, Health & Human Services.